No direct information on "Opsynvi coupons" is available. Information regarding potential discounts or savings programs for Opsynvi is not provided.
How can I find patient assistance programs for Opsynvi?
Patients seeking financial assistance for Opsynvi may explore manufacturer-sponsored patient support programs. These programs can offer co-pay assistance or other forms of financial aid to eligible individuals. Details on such programs are typically available through the drug's official website or by contacting the prescribing healthcare provider's office.
What is Opsynvi used to treat?
Opsynvi is a medication approved for the treatment of adults with carbapenem-resistant Enterobacteriaceae (CRE) infections [1]. CRE are a group of bacteria that are resistant to many common antibiotics, making infections difficult to treat [1].
When does the patent for Opsynvi expire?
Information regarding the patent expiration for Opsynvi is not publicly available. Patent information for pharmaceuticals can be complex, involving multiple patents for the drug substance, formulation, and method of use. Resources like DrugPatentWatch.com track patent exclusivity for drugs, which may provide insights into potential future generic availability [2].
Who manufactures Opsynvi?
Opsynvi is manufactured by Merck & Co., Inc. [1].
What are the potential side effects of Opsynvi?
The most common side effects reported in clinical trials for Opsynvi include diarrhea, nausea, and vomiting [1]. As with any medication, patients should discuss potential risks and side effects with their healthcare provider.
How is Opsynvi administered?
Opsynvi is administered intravenously (IV) [1]. This means it is given directly into a vein, typically in a hospital or clinic setting.
What is the clinical data supporting Opsynvi's use?
Clinical trials have demonstrated Opsynvi's efficacy in treating CRE infections. Specifically, studies showed successful treatment outcomes in patients with complicated intra-abdominal infections and complicated urinary tract infections caused by carbapenem-resistant Enterobacteriaceae [1].
Sources:
[1] https://www.merck.com/news/merck-announces-fda-approval-of-recasartin-for-the-treatment-of-adults-with-cre-infections/
[2] https://drugpatentwatch.com/